Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from SanBio Co ( (JP:4592) ) is now available.
SanBio Co., Ltd. reported financial results for the fiscal year ending January 31, 2025, highlighting a foreign exchange gain of 622 million yen and a foreign currency translation adjustment of negative 642 million yen. The company also recorded 113 million yen in stock issuance expenses, a 9 million yen gain from the reversal of share acquisition rights, and deferred income taxes of negative 128 million yen, reflecting its complex financial activities and their impact on earnings performance.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development of regenerative cell therapies. The company is known for its innovative treatments aimed at addressing unmet medical needs, particularly in the field of neurological disorders.
YTD Price Performance: 40.86%
Average Trading Volume: 1,013
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $558.9M
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue